Swords of cell death: Caspase activation and regulation

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 2, 2010, Pages 271-280

  Alenzi, Faris Q ^a   Lotfy, Mahmoud ^b   Wyse, Richard KH ^c  

^a PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b MENOUFIA UNIVERSITY   (Egypt)

^c Science and Technology   (United Kingdom)

Author keywords

Apoptosis; Caspases; DNA damage; Fas

Indexed keywords

EID: 78650707134     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Blanchard H, Donepudi M, Tschopp M, et al (2000). Caspase-8 specificity probed at subsite S(4): crystal structure of the caspase-8-Z-DEVD-cho complex. J Mol Biol, 302, 9-16.
2. Boatright KM, Renatus M, Scott FL, et al (2003). A unified model for apical caspase activation. Mol Cell, 11, 529-541.
3. Boldin MP, Goncharov TM, Goltsev YV, Wallach D (1996). Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell, 85, 803-15.
4. Bratton SB, MacFarlane M, Cain K, Cohen GM (2000). Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res, 256, 27-33.
5. Buggins AGS, Pepper CJ (2010). The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res. (Article in press and available online). doi:10.1016/j.leukres.2010.03.011.
6. Bump NJ, Hackett M, Hugunin M, et al (1995). Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science, 269, 1885-8.
7. Campo ML (2009). Apoptosis. In Salido GM, Rosado JA (Eds). Apoptosis: involvement of oxidative stress and intracellular Ca2+ homeostasis. Springer. DOI 10.1007/978-1-4020-9873-4.
8. Cerretti DP, Kozlosky CJ, Mosley B, et al (1992). Molecular cloning of the interleukin-1 beta converting enzyme. Science, 256, 97-100.
9. Chai J, Wu Q, Shiozaki E, Srinivasula SM, Alnemri ES, Shi Y (2001). Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding. Cell, 107, 399-407.
10. Chang DW, Xing Z, Capacio VL, Peter ME, Yang X (2003). Interdimer processing mechanism of procaspase-8 activation. EMBO J, 22, 4132-42.
11. Chen GG, Lai PBS (Eds) (2009). Apoptosis in carcinogenesis and chemotherapy: apoptosis in Cancer. Springer Science + Business Media B.V.. DOI 10.1007/978-1-4020-9597-9.
12. Chen M, Orozco A, Spencer DM, Wang J (2002). Activation of initiator caspases through a stable dimeric intermediate. J Biol Chem, 277, 50761-7.
13. Chen ZX, Pervaiz S (2009). BCL-2: pro-or anti-oxidant? Frontiers Biosci, 1, 263-8.
14. Cheng EHY, Kirsch DG, Clem RJ, et al (1997). Conversion of Bcl-2 to a Bax-like death effector by caspases. Science, 278, 1966-8.
15. Chinnaiyan AM, Orth K, O'Rourke K, et al (1996). Molecular ordering of the cell death pathway -Bcl-2 and Bcl-x(L) function upstream of the CED-3-like apoptotic proteases. J Biol Chem, 271, 4573-6.
16. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Rad Biol Med, 48, 749-62.
17. Clem R, Cheng EH, Karp CL, et al (1998). Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA, 95, 554-559.
18. Cryns V, Yuan J (1998). Proteases to die for. Genes Dev, 12, 1551-70.
19. da Fonseca RR., Kosiol C, Vinař T, Siepel A, Nielsen R (2010). Positive selction on apoptosis related genes. FEBS Lett, 584, 469-76.
20. Deng X, Gao F, May WS (2009). Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood, 113, 422-8.
21. Deveraux QL, Stennicke HR, Salvesen GS, Reed JC (1999). Endogenous inhibitors of caspases. J Clin Immunol, 19, 388-389.
22. Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997). X-linked IAP is a direct inhibitor of cell death proteases. Nature, 388, 300-4.
23. Donehower LA, Harvey M, Slagle BL, et al (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-21.
24. Duan H, Dixit VM (1997). RAIDD is a new 'death' adaptor molecule. Nature, 385, 86-90.
25. Earnshaw WC, Martins LM, Kaufmann SH (1999). Mammalian capases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem, 68, 382-424.
26. Elkon KB (Ed) (2006). Apoptosis and its relevance to autoimmunity. Current directions in autoimmunity, Theofilopoulos AN (Series Ed). Volume 9, Karger.
27. Ellis RE, Yuan JY, Horvitz HR (1991). Mechanisms and functions of cell death. Annu Rev Cell Biol, 7, 663-98.
28. Elmore S (2007). Apoptosis: a review of programmed cell death. Toxicol Pathol, 35, 495-516.
29. Enari M, Sakahira H, Yokoyama H, et al (1998). A caspase activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 391, 43-50.
30. Engel T, Henshall DC (2009). Apoptosis, Bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis? Int J Physiol Pathophysiol Pharmacol, 1, 97-115.
31. Fesus L, Davies PJ, Piacentini M (1991). Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol, 56, 170-7.
32. Fuentes-Prior P, Salvesen GS (2004). The protein structures that shape caspase activity specificity, activation and inhibition. Biochem J, 384, 201-32.
33. Fulda S (2008). Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anti-Cancer Agents Medicinal Chem, 8, 533-9.
34. Fulda S (2009). Tumor resistance to apoptosis. Int J Cancer, 124, 511-5.
35. Fulda S (2010). Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol, ??, 1-6.
36. Fulda S, Debatin K-M (2008). Apoptosis signaling pathways in anticancer therapy. Curr Cancer Therapy Rev, 4, 14-20.
37. Fulda S, Pervaiz S (2010). Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol, 42, 31-8.
38. Galani V, Tatsaki E, Bai M, et al (2010). The role of apoptosis in the pathophysiology of Acute Respiratory Distress Syndrome (ARDS): An up-to-date cell-specific review. Path Res Pract, 206, 145-50.
39. Galluzzi L, Joza N, Tasdemir E, et al (2008). No death without life: vital functions of apoptotic effectors. Cell Death Differ, 15, 1113-23.
40. Galluzzi L, Maiuri MC, Vitale I, et al (2007). Cell death modalities: classification and pathophysiological implications. Cell Death Differ, 14, 1237-43.
41. Galluzzi L, Morselli E, Kepp O, et al (2010). Mitochondrial gateways to cancer. Mol Aspects Med, 311-20.
42. Goltsev YV, Kovalenko AV, Arnold E, et al (1997). CASH, a novel caspase homologue with death effector domains. J Biol Chem, 272, 19641-4.
43. Green DR., Kroemer G (2009). Cytoplasmic functions of the tumour suppressor p53. Nature, 458, 1127-30.
44. Gupta S (2000). Molecular steps of cell suicide: An insight into immune senescence. J Clin Immunol, 20, 229-39.
45. Gorman AM, Orrenius S, Ceccatelli S (1998). Apoptosis in neuronal cells: role of caspases. Neuroreport, 9, R49-55.
46. Han DK, Chaudhary PM, Wright ME, et al (1997). MRIT, a novel death- effector domain-containing protein, interacts with caspases and Bcl-XL and initiates cell death. Proc Natl Acad Sci USA, 94, 11333-8.
47. Hotchkiss RS, Nicholson DW (2006). Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol, 6, 813-22.
48. Hu Y, Benedict MA, Wu D, Inohara N, Núñez G (1998). Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA, 95, 4386-91.
49. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM (1997). I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem, 272, 17255-7.
50. Jänicke RU, Ng P, Sprengart ML, Porter AG (1998). Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem, 273, 15540-5.
51. Jänicke RU, Sprengart ML, Wati MR, Porter AG (1998). Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem, 273, 9357-60.
52. Jurasz P, Courtman D, Babaie S, Stewart DJ (2010). Role of apoptosis in pulmonary hypertension: From experimental models to clinical trials. Pharmacol Therapeutics, 126, 1-8.
53. Kothakota S, Azuma T, Reinhard C, et al (1997). Caspase-3 generated fragment of gelsolin: Effector of morphological changes in apoptosis. Science, 278, 294-8.
54. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S (2001). Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem, 276, 20633-40.
55. Lakhani SA, Masud A, Kuida K, ET AL (2006). Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science, 311, 847-51.
56. Lamkanfi M, Declercq W, Kalai M, Saelens X, Vandenabeele P (2002). Alice in caspase land. A phylogenetic analysis of caspases from worm to man. Cell Death Differ, 9, 358-361.
57. Lamkanfi M, Kanneganti T-D (2010). Caspase-7: A protease involved in apoptosis and inflammation. Int J Biochem Cell Biol, 42, 21-4.
58. Li J, Yuan J (2008). Caspases in apoptosis and beyond. Oncogene, 27, 6194-206.
59. Li H, Zhu H, Xu CJ, Yuan J (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94, 491-501.
60. Liu X, Zou H, Slaughter C, Wang X (1997). DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell, 89, 175-84.
61. Lockshin RA, Zakeri Z (2007). Cell death in health and disease. J Cell Molec Med, 11, 1214-1224.
62. Loegering DA, Ruchaud S, Earnshaw WC, Kaufmann SH (2006). Evaluation of the role of caspase-6 in anticancer drug induced apoptosis. Cell Death Differ, 13, 346-347.
63. Lu C, El-Deiry WS (2009). Targeting p53 for enhanced radio and chemo-sensitivity. Apoptosis, 14, 597-606.
64. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94, 481-90.
65. Makris D, Vrekoussis T, Izoldi M, et al (2009). Increased apoptosis of neutrophils in induced sputum of COPD patients. Respir Med, 103, 1130-5.
66. Medema JP, Scaffidi C, Kischkel FC, et al (1997). FLICE is activated by association with the CD95 death-inducing signalling complex (DISC). EMBO J, 16, 2794-804.
67. Muñoz LE, Peter C, Herrmann M, Wesselborg S, Lauber K (2010). Scent of dying cells: the role of attraction signals in the clearance of apoptotic cells and its immunological consequences. Autoimmunity Rev, 9, 425-30.
68. Muzio M, Chinnaiyan AM, Kischkel FC, et al (1996). FLICE, anovel FADD-homologus ICE/CED-3-like protease, is recruited to CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85, 817-27.
69. Nagata S, Golstein P (1995). The Fas death factor. Science, 267, 1449.
70. Nicholson DW, Thornberry NA (1997). Caspases: Killer proteases. Trends Biochem Sci, 22, 299-306.
71. Oppenheim JJ, Yang D (2005). Alarmins: chemotactic activators of immune responses. host pathogen interactions/immunological techniques. Curr Opinion Immunol, 17, 359-65.
72. Owens GP, Hahn WE, Cohen JJ (1991). Identification of mRNAs associated with programmed cell death in immature thymocytes. Mol Cell Biol, 11, 4177-88.
73. Pennarun B, Meijer A, de Vries EGE, et al (2010). Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta, 1805, 123-40.
74. Porter AG, Janicke RU (1999). Emerging roles of caspase-3 in apoptosis. Cell Death Differ, 6, 99-104.
75. Raff MC (1992). Social controls on cell survival and cell death. Nature, 356, 397-400.
76. Rasper DM, Vaillancourt JP, Hadano S, et al (1998). Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ, 5, 271-88.
77. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997). The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J, 16, 6914-6925.
78. Saikumar P, Dong Z, Mikhailov V, et al (1999). Apoptosis: definition, mechanisms, and relevance to disease. Am J Med, 107, 489-506.
79. Saleh M, Mathison JC, Wolinski MK, et al (2006). Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature, 440, 1064-8.
80. Saleh M, Vaillancourt JP, Graham RK, et al (2004). Differential modulation of endotoxin responsiveness by humancaspase-12 polymorphisms. Nature, 429, 75-9.
81. Scaffidi C, Fulda S, Srinivasan A, et al (1998). Two CD95 (APO-1/Fas) signalling pathways. EMBO J, 17, 1675-87.
82. Scaffidi C, Medema JP, Krammer PH, Peter ME (1997). FLICE is predominantly expressed as two functionally active isoforms caspase-8/a and caspase-8/b. J Biol Chem, 272, 26953-8.
83. Sharad K (1999). Regulation of caspase activation in apoptosis: implications in pathogenesis and treatment of disease. Clin Exp Pharm Physiol, 26, 295-303.
84. Shi M. Vivian CJ, Lee KJ, et al (2009). DNA-PKcs-PIDDosome: a nuclear caspase-2- activating complex with role in G2/M checkpoint maintenance. Cell, 136, 508-20.
85. Slee EA, Harte MT, Kluck RM, et al (1999).Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8 and -10 in a caspase-9-dependent manner. J Cell Biol, 144, 281-92.
86. Sluyser M (Ed) (2005). Apoptosis in Normal Development and Cancer. Taylor & Francis Inc.
87. Speidel D (2010). Transcription-independent p53 apoptosis: an alternative route to death (Review). Trends in Cell Biology, 20, 14-24.
88. Srinivasula SM, Ahmad M, Ottilie S, et al (1997). FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem, 272, 18542-5.
89. Steemans M, Goossens V, Van de Craen M, et al (1998). A caspase-activated factor (Caf) induces mitochondrial membrane depolarization and cytochrome C release by a non-proteolytic mechanism. J Exp Med, 188, 2193-8.
90. Stegh AH, Barnhart BC, Volkland J, et al (2002). Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J Biol Chem, 277, 4351-60.
91. Stegh AH, Herrmann H, Lampel S, et al (2000). Identification of the cytolinker plectin as a major early in vivo substrate for caspase 8 during CD95- and tumor necrosis factor receptor-mediated apoptosis. Mol Cell Biol, 20, 5665-79.
92. Steller H (1995). Mechanisms and genes of cellular suicide. Science, 267, 1445-8.
93. Taylor RC, Cullen SP, Martin SJ (2008). Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol, 9, 231-41.
94. Thornberry NA, Rano TA, Peterson EP, et al (1997). A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem, 272, 17907-11.
95. Xue D, Horvitz HR (1995). Inhibition of the Caenorhabditis elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein. Nature, 377, 248-51.
96. Wallach D, Varfolomeev EE, Malinin NL, et al (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol, 17, 331.
97. Wolff S, Erster S, Palacios G, et al (2008). p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res, 18, 733-44.
98. Woo M, Woo M, Hakem R, et al (1998). Essential contribution of caspase-3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev, 12, 806-19.
99. Wyllie AH, Kerr JF, Currie AR (1980). Cell death: The significance of apoptosis. Int Rev Cytol, 68, 251-306.
100. Vakifahmetoglu-Norberg H, Zhivotovsky B (2010). The unpredictable caspase-2: what can it do? Trends Cell Biol, 20, 150-9.
101. Vaseva AV, Moll UM (2009). The mitochondrial p53 pathway. Biochim Biophys Acta, 1787, 414-20.
102. Vazquez A, Bond EE, Levine AJ, Bond GL (2008). The genetics of the p53 pathway, apoptosis and cancer therapy. Nature Rev Drug Discovery, 7, 979-87.
103. Vincenz C, Dixit VM (1997). Fas associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95-and p55-mediated death signalling. J Biol Chem, 272, 6578-83.
104. Yang X, Chang HY, Baltimore D (1998). Autoproteolytic activation of pro- caspases by oligomerization. Mol Cell, 1, 319-25.
105. Yin X-M, Dong Z (Eds) (2003). Essentials of Apoptosis: a Guide for Basic and Clinical Research. Humana Press Inc.
106. Youle RJ, Strasser A (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol, 9, 47-59.
107. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR (1993). The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell, 75, 641-52.
108. Zhivotovsky B, Orrenius S (2010). Cell death mechanisms: cross-talk and role in disease. Exp Cell Res (in press and available online). doi:10.1016/j.yexcr.2010.02.037.